Advertisement

Topics

Latest "Trends Financial Access Prescription Drugs Among Cancer Survivors" News Stories

21:26 EST 21st February 2019 | BioPortfolio

Here are the most relevant search results for "Trends Financial Access Prescription Drugs Among Cancer Survivors" found in our extensive news archives from over 250 global news sources.

More Information about Trends Financial Access Prescription Drugs Among Cancer Survivors on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Trends Financial Access Prescription Drugs Among Cancer Survivors for you to read. Along with our medical data and news we also list Trends Financial Access Prescription Drugs Among Cancer Survivors Clinical Trials, which are updated daily. BioPortfolio also has a large database of Trends Financial Access Prescription Drugs Among Cancer Survivors Companies for you to search.

Showing "Trends Financial Access Prescription Drugs Among Cancer Survivors" News Articles 1–25 of 42,000+

Thursday 21st February 2019

PlantResistance Stimulants Global Market Research and Forecast, 20152025 [Report Updated: 01011970] Prices from USD $2200

SummaryThe PlantResistance Stimulants report provides an independent information about the PlantResistance Stimulants industry supported by extensive research on factors such as industry segmentssize trends, inhibitors, dynamics, drivers, opportunities challenges, environment policy, cost overview, porter's five force analysis, and key companies profiles including business overview and recent...


Scientists uncover how high-fat diet drives colorectal cancer growth https://medicalxpress.com/news/2019-02-scientists-uncover-high-fat-diet-colorectal.html … FXR agonists curtail colorectal cancer progression. Maybe $ICPT should just forget about NA

Scientists uncover how high-fat diet drives colorectal cancer growth https://medicalxpress.com/news/2019-02-scientists-uncover-high-fat-diet-colorectal.html … FXR agonists curtail colorectal cancer progression. Maybe $ICPT should just forget about NASH and pivot to oncology ;) https://www.cell.com/cell/fulltext/S0092-8674(19)30099-6 …

Plantbased Squalane Global Market Research and Forecast, 20152025 [Report Updated: 01011970] Prices from USD $2200

SummaryThe Plantbased Squalane report provides an independent information about the Plantbased Squalane industry supported by extensive research on factors such as industry segmentssize trends, inhibitors, dynamics, drivers, opportunities challenges, environment policy, cost overview, porter's five force analysis, and key companies profiles including business overview and recent development.T...


Unplasticized Polyvinyl Chloride Global Market Research and Forecast, 20152025 [Report Updated: 01011970] Prices from USD $2200

SummaryThe Unplasticized Polyvinyl Chloride report provides an independent information about the Unplasticized Polyvinyl Chloride industry supported by extensive research on factors such as industry segmentssize trends, inhibitors, dynamics, drivers, opportunities challenges, environment policy, cost overview, porter's five force analysis, and key companies profiles including business overvie...

Scientists use Network Analysis to examine the relationships among 38 common symptoms reported by over 1300 #Cancer patients undergoing #chemotherapy: http://ow.ly/XoC130nMNwQ 

Scientists use Network Analysis to examine the relationships among 38 common symptoms reported by over 1300 #Cancer patients undergoing #chemotherapy: http://ow.ly/XoC130nMNwQ 

Progenity Announces Expansion of Board of Directors

Company Focused on Diagnostic and Therapeutic Precision Medicine Solutions in Prenatal and Perinatal Healthcare, Oncology, and Gastroenterology Progenity, Inc., a privately held biotechnology company, today announced the expansion of its board of directors with four new directors to support the company as it executes its plans to develop and com...

Particle Grade ZnO Global Market Research and Forecast, 20152025 [Report Updated: 01011970] Prices from USD $2200

SummaryThe Particle Grade ZnO report provides an independent information about the Particle Grade ZnO industry supported by extensive research on factors such as industry segmentssize trends, inhibitors, dynamics, drivers, opportunities challenges, environment policy, cost overview, porter's five force analysis, and key companies profiles including business overview and recent development.The...

Firmly on our way to becoming a fully integrated biopharma company

Revenues doubled in 2018 Key 2018 clinical results: FINCH 2 Phase 3 trial with filgotinib in rheumatoid arthritis (RA) met all primary and secondary endpoints, with consistent tolerability TORTUGA and EQUATOR Phase 2 trials with filgotinib in ankylosing spondylitis (AS) and psoriatic arthritis (PsA) met primary endpoints with consistent tolerability Initiated ISABELA, a gl...

Covalon Announces Conference Call to Discuss First Quarter Financial Results

Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, will be releasing its Fiscal 2019 First Quarter financial results on Tuesday February 26th, 2019, after markets close. A conference call to discuss the financial results will be held Wednesday February 27th, 2019, ...

Expanding its #immunotherapy pipeline in #Cancer as well as infectious and allergic diseases, @Merck buys @ImmuneDesign: http://ow.ly/G3z530nMN6i 

Expanding its #immunotherapy pipeline in #Cancer as well as infectious and allergic diseases, @Merck buys @ImmuneDesign: http://ow.ly/G3z530nMN6i 

Eng Highlights Important Treatment Considerations in mCRC

Cathy Eng, MD, FACP, discusses the current treatment options available for patients with metastatic colorectal cancer and highlights recent data in the space.

Spok Sets Date to Report 2018 Fourth Quarter and Full Year Results

Investor Conference Call Scheduled Spok Holdings, Inc. (NASDAQ: SPOK), the global leader in healthcare communications, today announced it will report operating results for the 2018 fourth quarter and full year ended December 31, 2018 on

Halo Labs Commences Trading on the OTCQB Venture Market in the United States under the Symbol AGEEF

Halo Labs Inc. ("Halo" or the "Company") (NEO: HALO, OTC: AGEEF, GERMANY: A9KN) is pleased to announce that OTC Markets Group Inc. has approved the trading of Halo Labs' shares on the OTCQB Venture Market. The company's shares will commence trading under the symbol AGEEF on February 22, 2019. The company's shares will continue t...

New AI Able to Identify, Predict Development of Cancer Symptom Clusters

NewsCancer patients who undergo chemotherapy could soon benefit from a new AI.

Alexion to Present at the 8th Annual SVB Leerink Global Healthcare Conference

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at the 8th Annual SVB Leerink Global Healthcare Conference in New York, NY on Wednesday, February 27, 2019 at 11:00 a.m., ET. An audio webcast of the presentation will be available live. You can access the webcast at: http://ir.alexion.com

Moderna to Report Fourth Quarter and Full Year 2018 Financial Results on Wednesday, March 6, 2019

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, March 6, 2019 to report its fourth quarter and full year 2018 ...

$BLUE Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Operational Progress https://www.businesswire.com/news/home/20190221005927/en/bluebird-bio-Reports-Fourth-Quarter-Full-Year …

$BLUE Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Operational Progress https://www.businesswire.com/news/home/20190221005927/en/bluebird-bio-Reports-Fourth-Quarter-Full-Year …

Dexcom Reports Fourth Quarter and Fiscal Year 2018 Financial Results

The Company also Announces Expansion and Reorganization of its Customer Support Functions DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2018. Fourth Quarter 2018 Highlights: Revenue grew 53% versus the same quarter of the prior year to $338.0...

U.S. FDA proposes new regulations for over-the-counter sunscreens

The U.S. Food and Drug Administration said on Thursday two of the 16 currently used main chemical ingredients in over-the-counter sunscreen products are considered safe, as part of a proposal https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements...

Cytokinetics Reports Fourth Quarter 2018 Financial Results

Company Provides 2019 Financial Guidance and Expected Milestones Reduced Operating Expenses vs. 2018; Over Two Years of Cash Based on Current Burn Rate Interim Analysis for GALACTIC-HF on Track for 1H 2019 Results from FORTITUDE-ALS Expected in Q2 2019 SOUTH … Continue reading →

Ironwood Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 at 11:00 a.m. Eastern Time at the Lotte New York Palace in New York. A live webcast of Ironwood’s presentation will be accessible through the Investors section of the ...

TherapeuticsMD Announces Fourth Quarter and Full-Year 2018 Financial Results

Successful Launch of IMVEXXY®, Strong PositiveTrends Continue for Prescriptions and Patient Refills BIJUVA™ Commercial Launch on Track for the Second Quarter of 2019 ANNOVERA™ Commercial Launch planned as Early as the Third Quarter of 2019 Conference Call Scheduled for 4:30 p.m. ET Today TherapeuticsMD, Inc. (NASDAQ:TXMD...

bluebird bio Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Operational Progress

- Strong 2018 marked by the company’s first European Marketing Authorization Application for LentiGlobin in transfusion-dependent β-thalassemia (TDT) – - Data across LentiGlobin studies in TDT and sickle cell disease (SCD) and bb21217 in multiple myeloma presented at American Society of Hematology (ASH) Annual Meeting – - En...

Tomorrow, FDA will post meeting materials for Tuesday's meeting of the Oncologic Drugs AdComm. #ODAC will review Karyopharm Therapeutics' #selinexor tablets, which is proposed for treatment of certain patients w/ relapsed refractory multiple myeloma. $KPT

Tomorrow, FDA will post meeting materials for Tuesday's meeting of the Oncologic Drugs AdComm. #ODAC will review Karyopharm Therapeutics' #selinexor tablets, which is proposed for treatment of certain patients w/ relapsed refractory multiple myeloma. $KPTI https://www.fda.gov/AdvisoryCommittee

STAAR Surgical Reports Fourth Quarter and Full Year 2018 Results

Fourth Quarter ICL Sales Rise 41%; Full Year 2018 ICL Sales Rise 48% GAAP Net Income of $0.02 Per Share in Fourth Quarter; $0.11 Per Share for Full Year 2018 STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial res...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks